Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide

Sara A. Monaghan, Lijun Dai, Markus Y. Mapara, Daniel P. Normolle, Susanne M. Gollin, Suzanne Lentzsch

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71%), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17%). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.

Original languageEnglish (US)
Pages (from-to)1965-1974
Number of pages10
JournalLeukemia and Lymphoma
Volume54
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Bone Marrow
Multiple Myeloma
Dexamethasone
Therapeutics
lenalidomide
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Cytogenetics
Stem Cells
Transplants

Keywords

  • Lenalidomide
  • Myelodysplastic syndrome
  • Myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. / Monaghan, Sara A.; Dai, Lijun; Mapara, Markus Y.; Normolle, Daniel P.; Gollin, Susanne M.; Lentzsch, Suzanne.

In: Leukemia and Lymphoma, Vol. 54, No. 9, 09.2013, p. 1965-1974.

Research output: Contribution to journalArticle

Monaghan, Sara A. ; Dai, Lijun ; Mapara, Markus Y. ; Normolle, Daniel P. ; Gollin, Susanne M. ; Lentzsch, Suzanne. / Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 9. pp. 1965-1974.
@article{da3626ca793b481f9fb60c8d05871035,
title = "Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide",
abstract = "Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71{\%}), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17{\%}). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.",
keywords = "Lenalidomide, Myelodysplastic syndrome, Myeloma",
author = "Monaghan, {Sara A.} and Lijun Dai and Mapara, {Markus Y.} and Normolle, {Daniel P.} and Gollin, {Susanne M.} and Suzanne Lentzsch",
year = "2013",
month = "9",
doi = "10.3109/10428194.2012.755177",
language = "English (US)",
volume = "54",
pages = "1965--1974",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide

AU - Monaghan, Sara A.

AU - Dai, Lijun

AU - Mapara, Markus Y.

AU - Normolle, Daniel P.

AU - Gollin, Susanne M.

AU - Lentzsch, Suzanne

PY - 2013/9

Y1 - 2013/9

N2 - Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71%), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17%). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.

AB - Lenalidomide (LEN) treatment in multiple myeloma (MM) results in a superior outcome. However, there is concern for increased myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) associated with LEN. Thus, bone marrow morphology and cytogenetics studies from 40 patients were evaluated for early signs of MDS prior to therapy, during therapy and at follow-up. Newly diagnosed patients with MM treated with LEN and dexamethasone (LD) alone or followed by autologous stem cell transplant (LD/ASCT), or patients with relapsed/refractory MM treated with LEN, bendamustine and dexamethasone (BLD) were included. One patient developed MDS. Baseline prevalence of mild morphologic myelodysplasia was highest in pretreated patients with MM (BLD, 71%), but was also seen in newly diagnosed patients (LD and LD/ASCT, 17%). The prevalence of myelodysplasia did not increase over time. Thus, this study did not reveal rapidly emerging MDS in 39 of 40 patients with MM treated with LEN. The development of MDS in one patient suggests that longer follow-up is needed for all.

KW - Lenalidomide

KW - Myelodysplastic syndrome

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=84882955178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882955178&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.755177

DO - 10.3109/10428194.2012.755177

M3 - Article

VL - 54

SP - 1965

EP - 1974

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -